Financial report
For the six months ended 30 June 2021 (unaudited)
|
|
|
|
|
|
|
|
|
|
|
Attributable to equity holders of the parent |
||||||
|
kEUR |
Share capital |
Share premium |
Translation reserve |
Treasury shares |
Other capital reserves |
Retained earnings |
Total |
|
|
|
|
|
|
|
|
|
|
Balance as at 1 January 2020 |
33,000 |
2,340 |
-2,694 |
0 |
0 |
116,770 |
149,416 |
|
Result for the period |
|
|
|
|
|
7,831 |
7,831 |
|
Re-measurement losses on defined benefit plans |
|
|
|
|
|
-95 |
-95 |
|
Currency exchange differences |
|
|
-299 |
|
|
|
-299 |
|
Total comprehensive income |
|
|
-299 |
0 |
0 |
7,736 |
7,437 |
|
|
|
|
|
|
|
|
|
|
Balance as at 30 June 2020 |
33,000 |
2,340 |
-2,993 |
0 |
0 |
124,506 |
156,853 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
kEUR |
Share capital |
Share premium |
Translation reserve |
Treasury shares |
Other capital reserves |
Retained earnings |
Total |
|
|
|
|
|
|
|
|
|
|
Balance as at 1 January 2021 |
33,000 |
2,340 |
-5,616 |
0 |
0 |
147,936 |
177,660 |
|
Result for the period |
|
|
|
|
|
24,623 |
24,623 |
|
Re-measurement losses on defined benefit plans |
|
|
|
|
|
2,988 |
2,988 |
|
Currency exchange differences |
|
|
1,553 |
|
|
|
1,553 |
|
Total comprehensive income |
0 |
0 |
1,553 |
0 |
0 |
27,611 |
29,164 |
|
|
|
|
|
|
|
|
|
|
Business restructuring |
-33,000 |
33,000 |
|
|
|
|
0 |
|
Incorporation of PolyPeptide Group AG |
273 |
|
|
|
|
|
273 |
|
Issue of new shares |
29 |
182,112 |
|
|
|
|
182,141 |
|
IPO-related costs charged to equity |
|
-4,652 |
|
|
|
|
-4,652 |
|
Purchase of own shares |
|
|
|
-5,464 |
|
|
-5,464 |
|
Share-based payment |
|
|
|
|
3,564 |
|
3,564 |
|
Transfer of own shares |
|
|
|
4,094 |
-4,094 |
|
0 |
|
Repayment by Draupnir Holding B.V. related to IPO bonus |
|
|
|
|
2,998 |
|
2,998 |
|
|
|
|
|
|
|
|
|
|
Balance as at 30 June 2021 |
302 |
212,800 |
-4,063 |
-1,370 |
2,468 |
175,547 |
385,684 |
The above interim consolidated statement of changes in equity should be read in conjunction with the accompanying notes.